A Phase 3 Randomized Placebo-controlled Multicenter Study of Upifitamab Rilsodotin (UpRi) as Post-Platinum Maintenance Therapy for Participants with Platinum-Sensitive Recurrent Ovarian Cancer (UP-NEXT).

Go Back to All Clinical Trials

A Phase 3 Randomized Placebo-controlled Multicenter Study of Upifitamab Rilsodotin (UpRi) as Post-Platinum Maintenance Therapy for Participants with Platinum-Sensitive Recurrent Ovarian Cancer (UP-NEXT).

Brief description of study

You can participate in this study if you are diagnosed with Platinum-Sensitive Recurrent Ovarian Cancer. In this study we will evaluate the study drug (Upifitamab rilsodotin) as post-platinum maintenance therapy for participants with platinum-sensitive recurrent ovarian Cancer.

Clinical Study Identifier: s21-01204

Principal Investigator: Bhavana Pothuri.

Other Investigators: Edna Shifteh, Michelle Diane Swanson Lightfoot, Marina Stasenko, Vania R. Baudin, Deanna Gerber, Christina Grace Wilson, Kathleen M Lutz, Kent Chan, Eva Chalas-Westermann, Kelly A Levine, Fabia Brisard Pierrot, Leslie R Boyd, Edward A Jimenez, Jaime Lynn Moyles, Erin Annette Reese, Whitfield B. Growdon.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Perlmutter Cancer Center

Clinical Trials & Research Studies